Related Experiment Video
Updated: Mar 13, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Mitochondrial division inhibitor Mdivi-1 ameliorates angiotensin II-induced endothelial dysfunction
Yu Chen1, Jing-Rong Lin2, Ping-Jin Gao1,3
1Laboratory of Vascular Biology, Institute of Health Science, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), University of Chinese Academy of Sciences, Shanghai 200025, China.
Abstract:
Mitochondrial fission can occur via activation of dynamin-related protein 1 (Drp1), which participates in the mitochondrial membrane scission process. The present study was designed to investigate the effect of angiotensin II (AngII) on mitochondrial fission and fusion in human umbilical vascular endothelial cells (HUVECs). And we further inquire into whether Mdivi-1, a newly identified pharmacological inhibitor of Drp1, can prevent endothelial dysfunction induced by AngII. The HUVECs were treated with AngII alone or in combination with Mdivi-1. Western blot was used to detect protein expressions of Drp1, endothelial nitric oxide synthase (eNOS) and apoptosis-related enzymes. MitoTracker Red and JC-1 dye were used to detect mitochondrial morphology and membrane potential, respectively. DCFH-DA probe was used to access intracellular reactive oxygen species (ROS) generation. Transwell assay was used to evaluate cell migration. Annexin V/PI staining was used to assess cellular apoptosis. The results showed that, in cultured HUVECs, AngII (1 × 10-7 mol/L, 12 h) treatment significantly upregulated the expression of Drp1 followed by increased apoptosis and decreased eNOS expression. The treatment of AngII resulted in a change in mitochondrial morphology from elongated to uniformly punctate organelles, which was accompanied by decreased mitochondrial membrane potential. Furthermore, Mdivi-1 significantly protected against AngII-induced endothelial dysfunction, as shown by increased mitochondrial membrane potential and eNOS expression, reduced ROS level, decreased apoptosis and migration ability. Taking together, our data suggest that inhibition of Drp1 with Mdivi-1 can restore AngII-induced endothelial dysfunction.
Insights
Angiotensin II (AngII) promotes endothelial dysfunction by increasing mitochondrial fission via dynamin-related protein 1 (Drp1). Mdivi-1, a Drp1 inhibitor, effectively reverses this dysfunction in human umbilical vascular endothelial cells.
Area of Science:
- Cell Biology
- Cardiovascular Research
- Mitochondrial Dynamics
Background:
- Mitochondrial fission, regulated by dynamin-related protein 1 (Drp1), is crucial for mitochondrial membrane scission.
- Endothelial dysfunction is implicated in various cardiovascular diseases.
Purpose of the Study:
- To investigate the impact of angiotensin II (AngII) on mitochondrial fission and fusion in human umbilical vascular endothelial cells (HUVECs).
- To determine if Mdivi-1, a Drp1 inhibitor, can mitigate AngII-induced endothelial dysfunction.
Main Methods:
- HUVECs were treated with AngII and/or Mdivi-1.
- Protein expression (Drp1, eNOS, apoptosis enzymes) analyzed via Western blot.
- Mitochondrial morphology, membrane potential, ROS generation, apoptosis, and cell migration were assessed using specific assays (MitoTracker Red, JC-1, DCFH-DA, Transwell, Annexin V/PI).
Main Results:
- AngII upregulated Drp1, increased apoptosis, and decreased eNOS expression in HUVECs.
- AngII altered mitochondrial morphology, leading to decreased mitochondrial membrane potential.
- Mdivi-1 treatment reversed AngII-induced endothelial dysfunction, improving mitochondrial potential, eNOS expression, and reducing ROS, apoptosis, and migration.
Conclusions:
- AngII induces endothelial dysfunction through Drp1-mediated mitochondrial fission.
- Inhibition of Drp1 by Mdivi-1 offers a protective effect against AngII-induced endothelial dysfunction.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Vasodilators
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

